EPB-004

N/A

Report date: 2023/04/02 14:45:30

Base Information

Drug NameEPB-004

Drug Alias NameEPB-004

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-CD123Anti-Myeloid cell surface antigen CD33Immunomodulators

TargetsInterleukin-3 receptor subunit alphaMyeloid cell surface antigen CD33

Therapy Area/IndicationsLymphoma, B-CellLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesElpiscience (Shanghai) Biopharma Ltd

China Registration ClassN/A

Develop Information

Active CompaniesElpiscience (Shanghai) Biopharma Ltd

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A